Scholarlink

Purpose <p>Pelvic floor dysfunction (PFD) is a highly prevalent sequela of gynecological cancer therapy (surgery, radiotherapy, chemotherapy), severely impacting quality of life (QoL). This systematic review evaluates evidence on prehabilitation interventions initiated before or during primary cancer therapy for improving pelvic floor muscle (PFM) function, reducing PFD symptoms, and enhancing QoL.</p> Methods <p>Following PRISMA 2020 guidelines, we searched MEDLINE, EMBASE, CINAHL, AMED, and Web of Science (2010–2025) for randomized controlled trials, cohort, and quasi-experimental studies. The review was prospectively registered (PROSPERO CRD42024580658). Included studies involved gynecological cancer patients receiving structured prehabilitation reporting PFM outcomes, PFD symptoms, or QoL. Risk of bias was assessed using JBI tools and GRADE.</p> Results <p>Five heterogeneous studies (<i>N</i> = 255; endometrial, ovarian, cervical, uterine, vulvar cancers; mean age 42–66 years) were included. One comparative cohort study demonstrated improved postoperative recovery (6MWT: 404&#xa0;m vs. 371&#xa0;m, <i>p</i> &lt; 0.001) and reduced complications (30% vs. 54%, <i>p</i> = 0.02). Uncontrolled studies showed potential benefits including improved lean mass (+ 1.0&#xa0;kg, <i>p</i> = 0.015), reduced incontinence (urinary: 53.6%→46.4%; fecal: 39.3%→25.0%), and enhanced QoL domains, with adherence 52–98%. However, direct evidence for improved objective PFM strength remains lacking. Evidence quality was “very low” (GRADE) due to heterogeneity, uncontrolled designs, small samples, and moderate-to-high risk of bias.</p> Conclusion <p>Prehabilitation is feasible but evidence is insufficient for definitive conclusions on pelvic-floor-specific efficacy. Findings are hypothesis-generating. High-quality RCTs with standardized PFD outcome measures are urgently needed. This review identifies critical knowledge gaps and provides recommendations for future research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of prehabilitation interventions on pelvic floor muscle outcomes in patients with gynecological cancers: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月20日

查看全文
  • Lawan Umar,
  • B.S Bappah,
  • A.U Gamawa,
  • B.A Tafida,
  • S Mohammed,
  • Z.U Dahiru,
  • A.A Tijjani,
  • U.M Bello

摘要

Purpose

Pelvic floor dysfunction (PFD) is a highly prevalent sequela of gynecological cancer therapy (surgery, radiotherapy, chemotherapy), severely impacting quality of life (QoL). This systematic review evaluates evidence on prehabilitation interventions initiated before or during primary cancer therapy for improving pelvic floor muscle (PFM) function, reducing PFD symptoms, and enhancing QoL.

Methods

Following PRISMA 2020 guidelines, we searched MEDLINE, EMBASE, CINAHL, AMED, and Web of Science (2010–2025) for randomized controlled trials, cohort, and quasi-experimental studies. The review was prospectively registered (PROSPERO CRD42024580658). Included studies involved gynecological cancer patients receiving structured prehabilitation reporting PFM outcomes, PFD symptoms, or QoL. Risk of bias was assessed using JBI tools and GRADE.

Results

Five heterogeneous studies (N = 255; endometrial, ovarian, cervical, uterine, vulvar cancers; mean age 42–66 years) were included. One comparative cohort study demonstrated improved postoperative recovery (6MWT: 404 m vs. 371 m, p < 0.001) and reduced complications (30% vs. 54%, p = 0.02). Uncontrolled studies showed potential benefits including improved lean mass (+ 1.0 kg, p = 0.015), reduced incontinence (urinary: 53.6%→46.4%; fecal: 39.3%→25.0%), and enhanced QoL domains, with adherence 52–98%. However, direct evidence for improved objective PFM strength remains lacking. Evidence quality was “very low” (GRADE) due to heterogeneity, uncontrolled designs, small samples, and moderate-to-high risk of bias.

Conclusion

Prehabilitation is feasible but evidence is insufficient for definitive conclusions on pelvic-floor-specific efficacy. Findings are hypothesis-generating. High-quality RCTs with standardized PFD outcome measures are urgently needed. This review identifies critical knowledge gaps and provides recommendations for future research.